Zoledronate and pamidronate depress neutrophil functions and survival in mice

British Journal of Pharmacology

Volumn 165, Issue 2, 2012, Pages 532-539

  Kuiper, J W P ^a   Forster, C ^a   Sun, C ^a   Peel, S ^a   Glogauer, M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

apoptosis; bisphosphonates; chemotaxis; NADPH oxidase; neutrophils; osteonecrosis of the jaw; Rho GTPases; zoledronate

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PAMIDRONIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ZOLEDRONIC ACID;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; IN VIVO STUDY; LIFESPAN; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NONHUMAN; PERITONITIS; PRIORITY JOURNAL;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CELL DIFFERENTIATION; CELL SURVIVAL; CHEMOTAXIS, LEUKOCYTE; DIPHOSPHONATES; IMIDAZOLES; LEUKOCYTE COUNT; MICE; MICE, INBRED C57BL; NADPH OXIDASE; NEUTROPHILS;

EID: 83755172746     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01592.x     Document Type: Article

References (39)

1. Alblas J, Ulfman L, Hordijk P, Koenderman L, (2001). Activation of Rhoa and ROCK are essential for detachment of migrating leukocytes. Mol Biol Cell 12: 2137-2145. (Pubitemid 33049705)
2. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, et al,. (1992). Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33: 1657-1663.
3. Benard V, Bokoch GM, (2002). Assay of Cdc42, Rac, and Rho GTPase activation by affinity methods. Methods Enzymol 345: 349-359. (Pubitemid 32954108)
4. Buitenhuis M, van Deutekom HW, Verhagen LP, Castor A, Jacobsen SE, Lammers JW, et al,. (2005). Differential regulation of granulopoiesis by the basic helix-loop-helix transcriptional inhibitors Id1 and Id2. Blood 105: 4272-4281. (Pubitemid 40720773)
5. Cancelas JA, Jansen M, Williams DA, (2006). The role of chemokine activation of Rac GTPases in hematopoietic stem cell marrow homing, retention, and peripheral mobilization. Exp Hematol 34: 976-985. (Pubitemid 44080381)
6. Christopher MJ, Link DC, (2007). Regulation of neutrophil homeostasis. Curr Opin Hematol 14: 3-8. (Pubitemid 44885605)
7. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A, (1992). Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80: 2012-2020.
8. Coukell AJ, Markham A, (1998). Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging 12: 149-168. (Pubitemid 28072569)
9. Dinauer MC, (2003). Regulation of neutrophil function by Rac GTPases. Curr Opin Hematol 10: 8-15. (Pubitemid 36020712)
10. Doeing DC, Borowicz JL, Crockett ET, (2003). Gender dimorphism in differential peripheral blood leukocyte counts in mice using cardiac, tail, foot, and saphenous vein puncture methods. BMC Clin Pathol 3: 3.
11. Glogauer M, Marchal CC, Zhu F, Worku A, Clausen BE, Foerster I, et al,. (2003). Rac1 deletion in mouse neutrophils has selective effects on neutrophil functions. J Immunol 170: 5652-5657. (Pubitemid 36617857)
12. Green JR, Rogers MJ, (2002). Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 55: 210-224. (Pubitemid 34774267)
13. Gu Y, Filippi MD, Cancelas JA, Siefring JE, Williams EP, Jasti AC, et al,. (2003). Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science 302: 445-449. (Pubitemid 37296270)
14. Gutteridge DH, Retallack RW, Ward LC, Stuckey BG, Stewart GO, Prince RL, et al,. (1996). Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study. Bone 19: 387-394. (Pubitemid 26370841)
15. Hansen T, Kunkel M, Weber A, James Kirkpatrick C, (2006). Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35: 155-160.
16. Hong JW, Nam W, Cha IH, Chung SW, Choi HS, Kim KM, et al,. (2010). Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia. Osteoporos Int 21: 847-853.
17. Kim JS, Diebold BA, Kim JI, Kim J, Lee JY, Park JB, (2004). Rho is involved in superoxide formation during phagocytosis of opsonized zymosans. J Biol Chem 279: 21589-21597. (Pubitemid 38656570)
18. de Koning JP, Soede-Bobok AA, Schelen AM, Smith L, van Leeuwen D, Santini V, et al,. (1998). Proliferation signaling and activation of Shc, p21Ras, and Myc via tyrosine 764 of human granulocyte colony-stimulating factor receptor. Blood 91: 1924-1933. (Pubitemid 28185493)
19. Maher BM, Dhonnchu TN, Burke JP, Soo A, Wood AE, Watson RW, (2009). Statins alter neutrophil migration by modulating cellular Rho activity-a potential mechanism for statins-mediated pleotropic effects? J Leukoc Biol 85: 186-193.
20. Majda-Stanislawska E, Krzeminski Z, (1998). The correlation between the numbers of some bacteria in human oral cavity and blood neutrophil count. FEMS Immunol Med Microbiol 21: 145-148. (Pubitemid 28329015)
21. Marx RE, Cillo JE Jr, Ulloa JJ, (2007). Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65: 2397-2410. (Pubitemid 350100982)
22. Nemzek JA, Bolgos GL, Williams BA, Remick DG, (2001). Differences in normal values for murine white blood cell counts and other hematological parameters based on sampling site. Inflamm Res 50: 523-527. (Pubitemid 32999716)
23. Pfister T, Atzpodien E, Bauss F, (2003). The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 191: 159-167. (Pubitemid 37329461)
24. Reid IR, (2009). Osteonecrosis of the jaw: who gets it, and why? Bone 44: 4-10.
25. Reid IR, Bolland MJ, Grey AB, (2007). Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41: 318-320. (Pubitemid 47199147)
26. Ridley AJ, (2001). Rho GTPases and cell migration. J Cell Sci 114: 2713-2722. (Pubitemid 32785451)
27. Russell RG, (2007). Bisphosphonates: mode of action and pharmacology. Pediatrics 119 (Suppl. 2): S150-S162. (Pubitemid 46397937)
28. Russell RG, Rogers MJ, (1999). Bisphosphonates: from the laboratory to the clinic and back again. Bone 25: 97-106. (Pubitemid 29322070)
29. Russell HV, Groshen SG, Ara T, Declerck YA, Hawkins R, Jackson HA, et al,. (2010). A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer 57: 275-282.
30. Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, et al,. (2008). Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26: 5465-5476.
31. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al,. (1991). Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095-2105.
32. Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF, (2009). Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 140: 61-66.
33. Serretti R, Core P, Muti S, Salaffi F, (1993). Influence of dichloromethylene diphosphonate on reactive oxygen species production by human neutrophils. Rheumatol Int 13: 135-138. (Pubitemid 24018728)
34. Shi Y, Zhang J, Mullin M, Dong B, Alberts AS, Siminovitch KA, (2009). The mDial formin is required for neutrophil polarization, migration, and activation of the LARG/RhoA/ROCK signaling axis during chemotaxis. J Immunol 182: 3837-3845.
35. Siddiqi M, Garcia ZC, Stein DS, Denny TN, Spolarics Z, (2001). Relationship between oxidative burst activity and CD11b expression in neutrophils and monocytes from healthy individuals: effects of race and gender. Cytometry 46: 243-246. (Pubitemid 32899795)
36. Teronen O, Konttinen YT, Lindqvist C, Salo T, Ingman T, Lauhio A, et al,. (1997). Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its inhibition by clodronate. J Dent Res 76: 1529-1537. (Pubitemid 127748945)
37. Walter C, Al-Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, et al,. (2008). Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54: 1066-1072.
38. Weiss HM, Pfaar U, Schweitzer A, Wiegand H, Skerjanec A, Schran H, (2008). Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 36: 2043-2049.
39. Zhang FL, Casey PJ, (1996). Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65: 241-269. (Pubitemid 26250610)